Evidence summary
Study design
Prospective, multicentre, randomised and single-blind. Patients were assigned in a 2:1 ratio to Supreme DES or a durable-polymer everolimus-eluting stent comparator.
Study population
The trial enrolled patients with acute or chronic coronary syndromes undergoing percutaneous coronary intervention. Full eligibility and exclusion criteria are provided in the registered protocol and primary publication.
Primary endpoint
The 12-month primary endpoint was target-lesion failure: a composite of cardiac death, target-vessel myocardial infarction or clinically driven target-lesion revascularisation.
Programme timeline
The primary paper reports enrolment from October 2017 to July 2019 across sites in North America, Europe and Japan, with follow-up planned through five years.